Deutsche Bank analyst Emmanuel Papadakis suggests that the s...

Deutsche Bank analyst Emmanuel Papadakis suggests that the state litigation overhang explains GSK's continued 20% discount versus value peers. He also sees a significant chance of a similar outcome to the dismissed core federal litigation.